2487 Stock Overview
Cutia Therapeutics operates as a biopharmaceutical company that develops a dermatology platform for skin and scalp diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Cutia Therapeutics Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$7.21 |
| 52 Week High | HK$32.60 |
| 52 Week Low | HK$5.57 |
| Beta | 0 |
| 1 Month Change | -8.62% |
| 3 Month Change | 2.27% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -67.15% |
Recent News & Updates
Shareholder Returns
| 2487 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 7.1% | 13.3% | 5.2% |
| 1Y | n/a | -38.9% | -9.1% |
Return vs Industry: Insufficient data to determine how 2487 performed against the Hong Kong Biotechs industry.
Return vs Market: Insufficient data to determine how 2487 performed against the Hong Kong Market.
Price Volatility
| 2487 volatility | |
|---|---|
| 2487 Average Weekly Movement | 16.9% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 14.8% |
| 10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 2487's share price has been volatile over the past 3 months.
Volatility Over Time: 2487's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 298 | Lele Zhang | www.cutiatx.com |
Cutia Therapeutics operates as a biopharmaceutical company that develops a dermatology platform for skin and scalp diseases. The company focuses on the dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. The company was incorporated in 2019 and is based in Shanghai, China with additional offices in Beijing, Wuxi and Hong Kong.
Cutia Therapeutics Fundamentals Summary
| 2487 fundamental statistics | |
|---|---|
| Market cap | HK$2.20b |
| Earnings (TTM) | -HK$2.12b |
| Revenue (TTM) | HK$148.67m |
14.8x
P/S Ratio-1.0x
P/E RatioIs 2487 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2487 income statement (TTM) | |
|---|---|
| Revenue | CN¥137.62m |
| Cost of Revenue | CN¥66.62m |
| Gross Profit | CN¥71.01m |
| Other Expenses | CN¥2.03b |
| Earnings | -CN¥1.96b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.44 |
| Gross Margin | 51.60% |
| Net Profit Margin | -1,426.91% |
| Debt/Equity Ratio | 14.0% |
How did 2487 perform over the long term?
See historical performance and comparison